Medpace Holdings, Inc. $MEDP Shares Sold by Swedbank AB

Swedbank AB cut its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 45.5% during the first quarter, HoldingsChannel reports. The firm owned 12,000 shares of the company’s stock after selling 10,000 shares during the quarter. Swedbank AB’s holdings in Medpace were worth $5,762,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Steigerwald Gordon & Koch Inc. purchased a new position in Medpace in the fourth quarter valued at $30,000. Elyxium Wealth LLC purchased a new position in Medpace in the fourth quarter valued at $30,000. Quarry LP acquired a new stake in Medpace in the third quarter valued at $35,000. Finally, Bayban acquired a new stake in Medpace in the fourth quarter valued at $44,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at $9,154,350. This represents a 44.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 20.50% of the stock is currently owned by company insiders.

Medpace Stock Up 0.5%

NASDAQ:MEDP traded up $2.73 during mid-day trading on Friday, reaching $538.23. 177,537 shares of the stock were exchanged, compared to its average volume of 312,394. The stock has a market capitalization of $15.37 billion, a P/E ratio of 33.83, a P/E/G ratio of 2.72 and a beta of 1.15. Medpace Holdings, Inc. has a 1 year low of $306.70 and a 1 year high of $628.92. The company has a 50 day simple moving average of $467.24 and a 200-day simple moving average of $496.03.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.74 by $0.54. The business had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company’s revenue was up 26.5% compared to the same quarter last year. During the same period in the prior year, the company earned $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Wall Street Analyst Weigh In

MEDP has been the subject of several analyst reports. Royal Bank Of Canada lowered their price objective on Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Weiss Ratings reissued a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Robert W. Baird restated a “neutral” rating and set a $547.00 target price (up from $477.00) on shares of Medpace in a research note on Wednesday. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and boosted their target price for the stock from $490.00 to $515.00 in a research note on Tuesday. Finally, Wall Street Zen downgraded Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Two investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $469.17.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.